Shortage of Bile Acid Sequestrants – Colestyramine Powder for Oral Suspension 4g (Questran and Questran Light), Colesevelam (Cholestagel) and Colestipol (Colestid)

Updated: 11th July 2019

Description of product affected

- Colestyramine is licensed for use in the following indications\textsuperscript{1,2}:
  - Primary prevention of coronary heart disease in men between 35 and 59 years of age and with primary hypercholesterolaemia who have not responded to diet and other appropriate measures.
  - Reduction of plasma cholesterol in hypercholesterolaemia, particularly in those patients who have been diagnosed as Fredrickson's Type II (high plasma cholesterol with normal or slightly elevated triglycerides).
  - Relief of pruritus associated with partial biliary obstruction and primary biliary cirrhosis.
  - Relief of diarrhoea associated with ileal resection, Crohn's disease, vagotomy and diabetic vagal neuropathy.
  - Management of radiation-induced diarrhoea.
- The dose used varies between 4g and 36g daily according to the indication.\textsuperscript{1,2}
- For relief of diarrhoea, it is common practice to use colestyramine off-label to treat "bile acid diarrhoea" where considered clinically appropriate. In Cambridgeshire and Peterborough colestyramine is recommended first line for the management of bile acid malabsorption (unlicensed indication).
- Colestyramine is also used to help reduce the volume of jejunal and ileostomy outputs as a consequence of bowel resection for any cause,\textsuperscript{3} and in patients with myeloma treatment induced diarrhoea that is unresponsive to loperamide.\textsuperscript{4}
- Colesevelam\textsuperscript{5} has a much more restricted range of licensed indications limited to treatment of hypercholesterolaemia and is recommended in Cambridgeshire and Peterborough as second line therapy for bile acid malabsorption after colestyramine and where conventional anti-diarrhoea medication have failed.\textsuperscript{6}
- Colestipol\textsuperscript{7,8} is restricted to treatment of hypercholesterolaemia and is NON-FORMULARY in Cambridgeshire and Peterborough.
Background

Colestyramine

- Bristol-Myers Squibb (BMS) are currently the only supplier of colestyramine (Questran and Questran Light) and they are facing manufacturing difficulties.

- BMS are transferring both products Questran and Questran Light to Cheplapharm at the end of July 2019.

- Questran sachets are currently unavailable. It is not yet confirmed when the new manufacturer will be in a position to make supplies available.

- Questran Light sachets are currently available. The Emergency Order Process through Alliance Healthcare has been lifted and supplies should be available through normal wholesaler routes.

- Supplies of Questran Light are able to support demand for patients who take Questran or Questran Light sachets. BMS are also transferring Questran Light to Cheplapharm, but it is hoped that this will not impact adversely on continuity of supplies.

Colesevelam

- Cholestagel (colesevelam): currently out of stock. Resupply date 16th July.

Colestipol

- Colestid Orange (colestipol) 5g granules: currently in stock but will be out of stock from mid-July and not expected back until October 2019.

- Colestid (colestipol) granules 5g (plain): currently in stock but only sufficient to support the patients currently taking the colestipol either as plain granules or as Colestid Orange.

Alternative agents and management options

- Given the current issues with all of these agents it would seem prudent to keep patients on their existing treatment for as long as supplies remain available provided they are benefitting from treatment.

- If there is a need to switch patients between treatments the following factors should be taken into consideration:
  
  o Both Questran and Questran Light sachets contain 4g anhydrous colestyramine per sachet.

  o Questran Light contains 30mg of aspartame per sachet (whereas Questran contains about 3.8g sugar) and this may lead to tolerability issues in some patients with IBS.6

  o In switching patients between colestipol (5g sachet) and colestyramine (4g sachet) (or vice versa) it would seem appropriate to switch on a sachet for sachet basis and then titrate according to response if needed (with specialist input if appropriate).

  o There is no clear guidance on switching from colesevelam to colestyramine. If this turns out to be the only option available, specialist advice will be required. Patient and carers as appropriate
should be counselled about any change to their medication BEFORE any change is made.

**Pruritus**

- For patients with pruritus due to liver or biliary problems who do not achieve adequate benefit from treatment with a bile acid sequestrant, there are a number of alternative treatments available.9,10
- Specialist advice may be needed to ensure that symptom control is maintained.

**Urgent Action**

**For GP practices:**

- Questran sachets
  - GP practices should urgently identify patients prescribed Questran sachets to ensure patients have sufficient stock of their medication to last during the shortage period.
  - Where patients do not have sufficient supplies, practices should liaise with pharmacies directly to ascertain their stock levels as different pharmacies use a range of wholesalers. Questran Light, where this is clinically appropriate for the patient may be ordered via the normal ordering process.
  - Prescriptions for Questran Light sachets should be made on an acute basis and patients switched back to their normal product when supplies of Questran sachets resume.
  - Counsel the patient and their carers as appropriate about any change to their medication BEFORE any change is made.

- Cholestagel (colesevelam)
  - GP practice should urgently identify patients prescribed Cholestagel (colesevelam) to ensure patients have sufficient stock of their medication to last during the shortage period.
  - Specialist advice will be required to switch to an alternative.
  - Patient and carers as appropriate should be counselled about any change to their medication BEFORE any change is made.

**For pharmacies:**

- Support by checking your current stock levels of these products and informing your local practices.
- Support GPs in counselling patients regarding any change to their medication.

**References**

3. Personal communication – Chair British Society of Gastroenterology Research Committee
4. Personal communication – Chief Pharmacist St Marks Hospital London and Haematology Pharmacist, Guys & St Thomas’ NHS Foundation Trust.
6. NICE. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant

7. Pfizer Limited. COLESTID Orange 5g. SPC, date of revision of the text, 02/2015: https://www.medicines.org.uk/emc/product/129/spc

8. SANOFI. Cholestagel 625 mg film-coated tablets. SPC, date of revision of the text. 05 April 2017: https://www.medicines.org.uk/emc/product/6142

9. Management of pruritis associated with cholestasis. UpToDate (subscription only)

10. Personal communication – liver specialist pharmacist Kings Hospital London

Acknowledgements
- Professor Ramesh P Arasaradnam, Consultant Gastroenterologist, Chair British Society of Gastroenterology Research Committee, Deputy Lead CRN (Gastroenterology) West Midlands
- Michelle O’Connor, Chair of BAD UK, Bile Acid Diarrhoea Support (https://www.bad-uk.org/)
- Scott Mercer, Specialist pharmacist rheumatology, Guy’s and St Thomas’ NHS Foundation Trust Specialist Liver Pharmacist, Kings College Hospital
- Chief Pharmacist, St Marks Hospital London North West University NHS Foundation Trust
- Haematology Pharmacist, Guy’s and St Thomas’ NHS Foundation Trust
- Gastroentrology Pharmacist, Guy’s and St Thomas’ NHS Foundation Trust.

Original document prepared by:
David Erskine, London and South East Regional Medicines Information, Guy’s and St Thomas’ NHS Foundation Trust, 31 May 2018, updated 11 June 2019: email: medicinesinformation@gstt.nhs.uk

Document modified by and for all correspondence please contact:
Cambridgeshire and Peterborough Clinical Commission Group, Medicines Optimisation Team. Published 26 June 2019, reviewed and amended 11th July 2019; email: CAPCCG.prescribingpartnership@nhs.net.

Disclaimer: This memo can be adapted for local use. The content does not reflect national guidance. Some of this memo is based on clinical opinion from practitioners. Users should bear this in mind in deciding whether to base their policy on this document. Individual trusts should ensure that procedures for unlicensed medicines are followed where a foreign import drug is required in the interim. Any decision to prescribe off-label must take into account the relevant GMC guidance and NHS Trust governance procedures for unlicensed medicines. Prescribers are advised to pay particular attention to the risks associated with using unlicensed medicines or using a licensed medicine off-label. As with all prescribing, the prescriber is medically and legally responsible for the prescriptions they sign and for their decisions and actions when they supply and administer medicines or authorise or instruct others to do so.